Skip to main content
Premium Trial:

Request an Annual Quote

ARUP Licenses Epigenomics' Cancer Biomarker

NEW YORK (GenomeWeb news) – ARUP Laboratories, a diagnostic testing services provider in Salt Lake City, has licensed a biomarker from Epigenomics for use in developing an early detection test for colorectal cancer.

Berlin, Germany-based Epigenomics said today that ARUP has signed a non-exclusive license to use the DNA methylated Septin 9 gene to develop a test for colorectal cancer from a patient's blood sample.

The company said that it has demonstrated that methylated DNA of the Septin 9 gene indicates colorectal cancer in the early stages.

"Having a simple blood test that can detect colorectal cancer will be a major step in the fight against this dreadful disease, which is often curable when caught in the early stages," ARUP's executive VP of Health Policy, External Affairs and Corporate Communication, Ronald Weiss, said in a statement.

"All too often, patients fail to undergo a colonoscopy or conduct other types of colorectal cancer screenings because they find these methods invasive, unpleasant or costly. A blood test for detecting colorectal cancer, will be a convenient option that complements other screening methods," Weiss added.

ARUP is the second lab partner to use the biomarker in a lab-developed test, following Quest Diagnostics. Abbott Molecular and Sysmex also have obtained rights to commercialize diagnostic tests based on the technology, Epigenomics CEO Geert Nygaard noted.

Financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.